Use of bioartificial and artificial liver support devices

Seminars in Liver Disease

Volumn 16, Issue 4, 1996, Pages 435-444

  Hughes, Robin D ^a   Williams, Roger ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

acute liver failure; artificial organs; hepatocyte cultures

Indexed keywords

ARTIFICIAL LIVER; CLINICAL PROTOCOL; EXTRACORPOREAL CIRCULATION; HUMAN; LIVER FAILURE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030453066     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007256     Document Type: Review

References (61)

1. Hughes RD, Williams R: Clinical experience with charcoal and resin haemoperfusion. Sem Liver Dis 6:164-73, 1986.
2. Harrison PM, Hughes RD, Forbes A, et al. Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure. J Hepatol 10:332-6, 1990.
3. Nakamura T. Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-3, 1989.
4. Strain A, Ismail T, Tsubouchi H, et al: Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest 87:1853-7, 1991.
5. Hughes RD, Zhang L, Tsubouchi H, et al: Plasma hepatocyte growth factor and biliprotein levels in fulminant hepatic failure. J Hepatol 20:106-11, 1994.
6. Rozga J, Williams F, Ro M-S, et al: Development of a bioartificial liver: properties and function of a hollow-fibre module inoculated with liver cells. Hepatology 17:258-65, 1993.
7. Sussman NL. Chong MG, Koussayer T, et al: Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 16:60-5, 1992.
8. Ringe B, Pichlmayr R, Lubbe N, et al: Total hepatectomy as temporary approach to acute hepatic or primary graft failure. Transplant Proc 20:552-7. 1988.
9. Harrison PM, Wendon JA, Gimson AES, et al: Effect of total hepatectomy with and without orthotopic liver transplantation on systemic hemodynamics and oxygen-transport variables in fulminant hepatic failure. Gut 32:A837, 1991.
10. Basile AS. Harrison PM, Hughes RD, et al: The relationship between plasma benzodiazepine receptor ligand concentrations and the severity of hepatic encephalopathy. Hepatology 19:112-21, 1994.
11. Zieve L, Doizaki WM, Zieve FJ: Synergism between mercaptans and ammonia or fatty acids in the production of coma: A possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 83:16-28, 1974.
12. Yamada H, Toda G, Yoshiba M, et al: Humoral inhibitor of rat hepatocyte DNA synthesis from patients with fulminant hepatic failure. Hepatology 19:1133-40, 1994.
13. Sato Y, Tsukada K, Matsumoto Y, Abo T: Interferon-gamma inhibits liver regeneration by stimulating major histocompatibility complex class II antigen expression by regenerating liver. Hepatology 18:340-6, 1993.
14. Theocharis SE, Margeli AP. Tsokos MG: Alpha 2b-imerferon inhibits liver regeneration after partial hepatectomy without affecting thymidine kinase activity. J Lab Clin Med 125:588-96, 1995.
15. Nagaki M, Hughes RD, Keane HM, et al: In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock 38:182-8, 1992.
16. Minuk GY, Gauthier T: The effect of gamma-aminobutyric acid on hepatic regenerative activity following partial hepatectomy in rats. Gastroenterology 104:217-21, 1993.
17. Nakamura T, Tomita Y, Hirai R, et al: Inhibitory effect of transforming growth factor α on DNA synthesis of adult rat hepatocytes in primary culture. Biochem Biophy Res Commun 133:1042-50, 1985.
18. Russell WE, Coffey RJ, Ouellette AJ, Moses HL. Type α transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci 85:5126-30, 1988.
19. Hughes RD, Cochrane AMG, Thomson AD, et al: The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Path 57:348-53, 1976.
20. Kondrup J, Almdal T, Vilstrup H, Tygstrup N: High volume plasma exchange in fulminant hepatic failure. Intl J Artif Organs 15:669-76, 1992.
21. Makowka L, Rotstein LE. Falk RE, et al: Studies into the mechanism of reversal of experimental acute hepatic failure by hepatocyte transplantation 1. Can J Surg 24:39-44, 1981.
22. Baumgartner D, LaPlante-O'Neill, Sutherland DER, Najarian JS: Effects of intrasplenic injection of hepatocytes, hepatocyte fragments and hepatocyte culture supematants on D-galactosamine-induced liver failure in rats. Eur Surg Res 15:129-35, 1983.
23. Gonzalez-Calvin J, Scully MF, Sauger Y, et al: Fibronectin in fulminant hepatic failure. Br Med J 285:1231-2, 1982.
24. Wyke RJ, Rajkovic IA. Eddleston ALWF, Williams R: Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut 21:643-9, 1980.
25. Harrison P, Degen SJ, Williams R, Farzaneh F: Hepatic expression of hepatocyte growth factor-like/macrophage-stimulating protein mRNA in fulminant hepatic failure. Lancet 344:27-9, 1994.
26. Canalese J, Gove CD, Gimson AES, et al: Reticuloendothelial System and hepatocyte function in fulminant hepatic failure. Gut 23:265-9, 1982.
27. Izumi S. Hughes RD, Langley PG, et al: Extent of the acute phase response in fulminant hepatic failure. Gut 35:982-6, 1994.
28. 1-antitrypsin complex in fulminant hepatic failure: re-lationship to bacterial infection and activation of coagulation. Clin Chim Acta 200:211-20, 1991.
29. Hilgier W, Oison JE: Brain ion and amino acid contents during oedema development in hepatic encephalopathy. J Neurochem 62:197-204, 1994.
30. Olafsson S, Gonstein J, Blei AT: Brain edema and intracranial hypertension in rats after total hepatectomy. Gastroenterology 108:1097-1103. 1995.
31. Weston MJ, Gazzard GB. Buxton BH, et al: Effects of haemoperfusion through charcoal or XAD-2 resin on an animal model of fulminant hepatic failure. Gut 15:482-6, 1974.
32. Horak J, Horky J, Rabl M: Haemoperfusion through activated charcoal in dogs with fulminant hepatic failure. Digestion 20:22-30, 1980.
33. Chang TMS. Lister C, Chirito E, et al: Effects of haemoperfusion rate and time of initiation of ACAC microencapsulated charcoal haemoperfusion on the survival of fulminant hepatic failure rats. Trans Amer Soc Artif Intern Organs 24:243-5, 1978.
34. Toledo-Pereyra LH: Role of activated carbon hemoperfusion in the recovery of livers exposed to ischemie damage. Arch Surg 120:462-5, 1985.
35. O'Grady JG, Gimson AES, O'Brien CJ, et al: Controlled triais of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94:1186-92, 1988.
36. Berk PD, Goldberg JD: Charcoal hemoperfusion plus ca change, plus c'est la meme chose. Gastroenterology 94:1228-30, 1988.
37. Ash SR, Blake DE, Carr DJ, et al: Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Intl J Artif Org 15:151-61, 1992.
38. Hughes RD, Pucknell A, Routley D, et al: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Intl J Artif Org 17:657-62, 1994.
39. Stange J, Ramlow W, Mitzner et al: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Org 17:809-13, 1993.
40. Weber C, Rajnoch C. Loth F, et al: The microspheres based detoxification system (MDS). A new extracorporeal blood purification procedure based on recirculated microspherical adsorbent particles. Intl J .Artif Org 17:595-602, 1994.
41. 4L Rozga J, Holzman MD, Ro M-S. et al: Development of a hybrid bioanificial liver. Ann Surg 217:502-11, 1993.
42. Shnyra A, Bocharov A, Bochkova N, Spirov V: Bioartificial liver using hepatocytes on biosilon microcarriers: Treatment of chemically induced acute hepatic failure in rats. Artif Org 15:189-97, 1991.
43. Jauregui HO, Mullon CJ-P, Trenkler D, et al: In vivo evaluation of a hollow fiber liver assist device. Hepatology 21:460-9, 1995.
44. Sielaff TD, Hu MY, Amiot B, et al: Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. J Surg Res 59:179-84, 1995.
45. Hughes RD, Williams R: Evaluation of extracorporeal liver devices. Liv Transpl Surg 1:200-6, 1995.
46. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM: Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 18:85-94. 1989.
47. Fox IJ, Langnas AN, Fristoe LW, et al: Successful application of extracorporeal liver perfusion: a technology whose time has come. Am J Gastroenterol 88:1876-81, 1993.
48. Chari RS, Collins BH, Magee JC, et al: Treatment of hepatic failure with ex vivo pig liver perfusion followed by liver transplantation. NEJM 331:234-7, 1994.
49. Collins BH. Chari RS. Magee JC, et al: Mechanisms of injury in porcine livers perfused with blood of patients with fulminant hepatic failure. Transplantation 58:1162-71, 1994.
50. Rozga J, Podesta L, LePage E, et al: A bioartificial liver to treat severe acute liver failure. Ann Surg 5:538-46, 1994.
51. Chen S. Watanabe FD, Rozga J. et al: Clinical experience with a bioartificial liver (BAL). Hepatology 22:203A. 1995.
52. Kelly JH, Koussayer T. He D, et al: Assessment of an extracorporeal liver assist device in anhepatic dogs. Artif Org 16:418-22, 1992.
53. Sussman NL, Kelly JH: Extracorporeal liver assist in the treatment of fulminant hepatic failure. Blood Purifie 11:170-4, 1993.
54. Sussman NL, Gisalon G, Conlin CA, Kelly JH: The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Org 18:390-6, 1994.
55. Ellis AJ, Wendon J, Hughes R, et al: A controlled trial of the Hepatix extracorporeal liver assist device (ELAD) in acute liver failure. Hepatology 20:140A, 1994.
56. Ellis AJ, Hughes RD, Wendon JA. et al: Pilot controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology (in press).
57. O'Grady JG, Alexander GL, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439-45, 1989.
58. 1 in acute liver failure. Intl J Artif Org 19:240-4, 1996.
59. Naka D, Ishii T. Shimomura T. et al: Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocyte. Exp Cell Res 209:317-24, 1993.
60. Gerlach J, Trost T, Ryan CJ, et al: Hybrid liver support system in a short term application on hepatectomized pigs. Intl J Artif Org 10:549-53, 1994.
61. Kawada M, Nagamon S, Aizaki H, et al: A new liver support system composed of functional human cells and a radial flow bioreactor. Hum Cell 7:95-100, 1994.